11.2 Pediatric Thyroid, Adrenal & Growth Hormone Disorders

Pediatric Thyroid, Adrenal & Growth Hormone Disorders

Quick Overview: Pediatric endocrine disorders encompass congenital and acquired disruptions of homeostatic feedback loops. Congenital hypothyroidism demands prompt universal newborn screening and immediate levothyroxine replacement within 14 days of birth to prevent permanent neurodevelopmental impairment (cretinism). Congenital Adrenal Hyperplasia (CAH) results from 21-hydroxylase deficiency, precipitating neonatal salt-wasting crises (hyponatremia, hyperkalemia, vascular collapse) and ambiguous genitalia in females, managed through lifelong glucocorticoid and mineralocorticoid replacement with mandatory illness stress dosing. Growth hormone deficiency produces proportional short stature with delayed bone age, reversed through daily bedtime subcutaneous somatropin injections.

Endocrine regulation in pediatrics directly governs cellular metabolism, linear growth, fluid-electrolyte balance, and sexual maturation. Because pediatric hormone insufficiencies often masquerade as benign feeding difficulties, behavioral issues, or constitutional growth variations, the certified pediatric nurse must possess keen assessment skills to identify hallmark cues and execute evidence-based pharmacotherapeutic plans.

---

1. Congenital Hypothyroidism (CH)

Congenital Hypothyroidism occurs in approximately 1 in 2,000 to 1 in 3,000 live births. It is one of the most common preventable causes of intellectual disability in children.

Pathophysiological Classification

• Thyroid Dysgenesis (85% of cases): Structural maldevelopment of the gland itself, encompassing thyroid aplasia (complete absence), hypoplasia (underdeveloped gland), or thyroid ectopia (gland located in an abnormal anatomical site, such as the base of the tongue [lingual thyroid]).
• Thyroid Dyshormonogenesis (10% to 15% of cases): Inborn enzymatic errors in thyroid hormone synthesis, iodine organification, or thyroglobulin processing, inherited in an autosomal recessive pattern.
• Central (Hypothalamic-Pituitary) Hypothyroidism (< 5%): Deficient thyrotropin-releasing hormone (TRH) or thyroid-stimulating hormone (TSH) secretion, often accompanied by other anterior pituitary hormone deficits.

Universal Newborn Screening & The Critical Therapeutic Window

• Screening Protocol: Performed on all neonates via dried blood spot collected on Guthrie filter paper from a heel stick between 24 and 48 hours of life.
• Biochemical Criteria: Primary screening assays detect elevated serum TSH and low total or free thyroxine (T4).
• Maternal Hormone Washout: Full-term neonates are transiently protected by transplacental transfer of maternal thyroxine (which provides approximately 25% to 50% of normal fetal thyroid levels). Consequently, clinical signs are notoriously subtle at birth.
• The 14-Day Window: To ensure normal cognitive outcomes, thyroid hormone replacement must be confirmed and initiated within the first 2 weeks of life. Delay beyond 4 to 6 weeks causes irreversible neurocognitive damage.

Hallmark Clinical Manifestations in the Infant

When congenital hypothyroidism goes unrecognized on initial screening or in home births lacking newborn screens, the infant progressively displays:

• Prolonged Physiological Jaundice: Unconjugated hyperbilirubinemia persisting beyond 14 days of life, caused by delayed hepatic glucuronyl transferase maturation.
• Feeding Difficulties & Lethargy: Poor latch, prolonged nursing times, choking spells during feeding, extreme somnolence ("good baby" who sleeps through the night without waking for feeds).
• Hypotonia & Constipation: Generalized muscular hypotonia ("floppy infant"), sluggish bowel motility, severe obstipation, and delayed meconium passage.
• Cranial & Facial Features: Persistently wide anterior fontanelle and open posterior fontanelle (> 0.5 cm) at birth; coarse facial features with puffiness, periorbital edema, and macroglossia (large, thick, protruding tongue leading to respiratory stridor and snoring).
• Integumentary & Thermoregulatory Findings: Hypothermia, cold and mottled extremities (cutis marmorata), dry scaly skin, coarse brittle hair, and prominent umbilical hernia.
• Cretinism (Untreated Outcome): Severe, permanent intellectual disability (IQ often < 50), stunted linear growth (skeletal dwarfism with short limbs), delayed dentition, ataxia, and sensorineural deafness.

---

2. Levothyroxine Administration & Nursing Safety Guidelines

Lifelong oral replacement with Levothyroxine Sodium (Synthroid) is the gold standard therapy, initiated at a starting dose of 10 to 15 mcg/kg/day.

Administration Protocols in Infancy

1. Crushing Technique: The prescribed commercial tablet must be crushed between two spoons and mixed with a very small volume (1 to 2 mL) of water, breast milk, or non-soy formula.
2. Oral Syringe Delivery: Administer the suspension directly into the infant's buccal mucosa or inner cheek using an oral syringe or small spoon.
3. CRITICAL WARNING — DO NOT PUT IN FULL BOTTLE: Never mix crushed levothyroxine into an entire 4-ounce or 8-ounce feeding bottle! If the infant fails to finish the bottle, an unknown fraction of the dose is lost, resulting in chronic undertreatment.
4. Administration Timing: Give once daily at the same time every morning on an empty stomach, at least 30 to 60 minutes before a feeding.

Nutrient & Drug Binding Interactions

Levothyroxine absorption occurs primarily in the jejunum and ileum and is highly sensitive to intraluminal chelating agents. The nurse must teach families that levothyroxine must NEVER be administered concurrently with:

• Soy-Based Infant Formulas: Soy protein severely binds thyroxine in the intestinal lumen, causing fecal excretion.
• Iron Supplements (Ferrous Sulfate): Ferrous ions form an insoluble chelate complex with levothyroxine.
• Calcium Supplements or Calcium-Fortified Juices: Calcium carbonate binds thyroxine and reduces bioavailability.
• Aluminum Hydroxide Antacids & Fiber Supplements.
• Clinical Rule: Separate levothyroxine administration from iron, calcium, or soy products by a minimum of 4 hours.

Clinical Monitoring Schedule

• Check serum free T4 and TSH at 2 and 4 weeks post-initiation, then every 1 to 2 months throughout the first year of life, and every 2 to 3 months between ages 1 and 3 years.
• Target Goals: Maintain serum free T4 in the upper half of the normal pediatric reference range and TSH in the normal range (0.5–2.0 mIU/L).
• Monitor for Signs of Overtreatment (Thyrotoxicosis): Tachycardia, systolic hypertension, elevated body temperature, excessive sweating, frequent watery stools, irritability, insomnia, and accelerated bone age maturation.

---

3. Acquired Thyroid Disorders: Hashimoto & Graves' Disease

Hashimoto Thyroiditis (Chronic Autoimmune Lymphocytic Thyroiditis)

• The most common cause of acquired hypothyroidism and goiter in school-age children and adolescents.
• Etiology: Autoantibodies against thyroid peroxidase (anti-TPO) and thyroglobulin (anti-Tg).
• Clinical Presentation: Deceleration of linear growth velocity (height percentiles fall across channels while weight percentiles remain stable or rise), firm, non-tender diffuse goiter, lethargy, cold intolerance, dry skin, coarse hair, bradycardia, delayed deep tendon reflex relaxation, and delayed onset of puberty.
• Management: Daily oral levothyroxine titrated to normalize TSH.

Pediatric Graves' Disease (Hyperthyroidism)

• Hyperthyroidism in children is almost universally caused by Graves' disease, mediated by Thyroid-Stimulating Immunoglobulins (TSI) stimulating the TSH receptor.
• Clinical Presentation: Heat intolerance, hyperhidrosis, palpitations, tachycardia, wide pulse pressure, weight loss despite ravenous appetite (polyphagia), fine tremors, emotional lability, declining school performance with attention deficits, smooth vascular goiter with an audible thyroid bruit, and exophthalmos (proptosis).
• Pharmacological Treatment:
  • Methimazole (Tapazole): First-line antithyroid drug that inhibits thyroid peroxidase. (Propylthiouracil [PTU] is black-box contraindicated in pediatrics due to unacceptable risks of fulminant hepatic necrosis and liver failure!).
  • Beta-Blockers (Propranolol): Used acutely to control adrenergic storm (tachycardia, hypertension, tremors).
• CRITICAL EXAM ALERT — AGRANULOCYTOSIS: Methimazole carries a rare but lethal risk of bone marrow suppression and agranulocytosis (absolute neutrophil count < 500/mcL). Nurses must explicitly educate parents to stop methimazole immediately and obtain an emergent Complete Blood Count (CBC) with differential if the child develops a sudden fever, sore throat (pharyngitis), mouth sores, or systemic infection!

---

4. Congenital Adrenal Hyperplasia (CAH)

Congenital Adrenal Hyperplasia encompasses a group of autosomal recessive disorders characterized by enzymatic deficiencies in the steroidogenic pathway of the adrenal cortex.

Pathophysiological Cascade of 21-Hydroxylase Deficiency

Greater than 90% to 95% of CAH cases result from a mutation in the CYP21A2 gene encoding 21-hydroxylase:

1. Block in Steroid Synthesis: Inability to convert 17-hydroxyprogesterone (17-OHP) to 11-deoxycortisol, and progesterone to deoxycorticosterone. This produces an absolute or relative deficiency of Cortisol (glucocorticoid) and Aldosterone (mineralocorticoid).
2. Loss of Negative Feedback: Deficient circulating cortisol fails to inhibit the anterior pituitary, triggering massive, persistent hypersecretion of Adrenocorticotropic Hormone (ACTH).
3. Adrenal Hyperplasia & Androgen Shunting: Excessive ACTH overstimulates the adrenal cortex, causing bilateral adrenal hyperplasia. Steroid precursors backed up behind the enzymatic block are shunted into the intact adrenal androgen pathway, creating severe overproduction of DHEA, androstenedione, and testosterone.

Clinical Phenotypes of Classic CAH

The Neonatal Salt-Wasting Adrenal Crisis

Aldosterone deficiency abolishes sodium reabsorption in the renal distal convoluted tubule and collecting duct, preventing normal potassium and hydrogen ion excretion:

• Biochemical Triad: Severe hyponatremia (serum Na < 130 mEq/L), hyperkalemia (serum K > 6.0–8.0 mEq/L), and metabolic acidosis.
• Clinical Progression: Poor feeding, failure to regain birth weight, projectile vomiting, diarrhea, severe dehydration, lethargy, weak peripheral pulses, mottled cool skin, progressive hypotension, cardiac arrhythmias (peaked T waves, widened QRS), and cardiovascular collapse.

---

5. CAH Pharmacological Management & Adrenal Crisis Protocols

Therapy for CAH is lifelong and aims to replace deficient hormones and suppress excess pituitary ACTH secretion.

Daily Maintenance Regimen

1. Glucocorticoid Replacement: Oral Hydrocortisone (Cortef) divided into 3 daily doses (typically 10 to 15 mg/m2/day). Hydrocortisone provides physiological cortisol replacement and suppresses excess ACTH, thereby normalizing adrenal androgen production and preventing virilization.
2. Mineralocorticoid Replacement: Oral Fludrocortisone Acetate (Florinef) (0.05 to 0.2 mg daily) to restore renal sodium reabsorption and normalize potassium balance.
3. Sodium Chloride Supplementation: Infants require 1 to 2 grams (17 to 34 mEq) of elemental sodium chloride solution or tablets added daily to feeds throughout the first year of life because infant formula and breast milk are naturally low in sodium.

Adrenal Stress Dosing ("Sick-Day Rules")

Under conditions of physical stress, normal physiological adrenal glands increase cortisol production up to 3- to 5-fold. Children with CAH cannot mount this response and will rapidly plunge into a fatal adrenal crisis unless exogenous glucocorticoids are augmented:

• Fever & Mild-to-Moderate Illness: When the child experiences a fever (temperature >= 38.5°C [101.3°F]), significant upper respiratory infection, gastroenteritis, or localized trauma (such as a bone fracture), the caregiver must DOUBLE or TRIPLE the oral hydrocortisone dose for 48 to 72 hours until the illness resolves.
• Mineralocorticoid Dosing: Fludrocortisone dose remains unchanged during stress dosing.
• Emergency Injectable Hydrocortisone (Solu-Cortef):
  • If the child is vomiting, unable to retain oral medications, severely lethargic, or suffering major trauma/surgery, oral steroids are useless.
  • The family must immediately administer an intramuscular (IM) injection of Hydrocortisone Sodium Succinate (Act-O-Vial / Solu-Cortef) into the vastus lateralis muscle:
    • Age < 3 years: 25 mg IM
    • Age 3 to 12 years: 50 mg IM
    • Age > 12 years: 100 mg IM
  • After injection, the caregiver must call 911 or transport the child immediately to the nearest emergency department for intravenous hydration (0.9% Normal Saline with 5% Dextrose) and electrolyte correction.
• Emergency Preparedness: Every child with CAH must wear a medical alert identification bracelet and have an emergency injectable Solu-Cortef kit accessible at home, daycare, and school.

---

6. Growth Hormone (GH) Deficiency & Hypopituitarism

Growth Hormone (somatotropin) is secreted by the somatotroph cells of the anterior pituitary under the pulsatile control of hypothalamic Growth Hormone-Releasing Hormone (GHRH) and Somatostatin.

Clinical Manifestations of Pediatric GH Deficiency

• Proportional Short Stature: Height falls significantly below the 3rd percentile or crosses two major percentile lines on standard growth curves. In contrast to skeletal dysplasias (achondroplasia) where limb shortening is disproportionate, GH-deficient children have normal body proportions (head-to-body and upper-to-lower segment ratios are normal).
• Normal Neonatal Dimensions: Birth weight and length are typically normal. Growth deceleration becomes noticeable in late infancy or toddlerhood, with linear growth velocity dropping below normal (< 4 to 5 cm/year).
• Facial Features ("Cherubic / Doll-Like"): Immature facial appearance with a prominent forehead (frontal bossing), depressed nasal bridge, crowded dentition with delayed tooth eruption, and high-pitched voice.
• Metabolic Profile: Increased abdominal and truncal subcutaneous adiposity (due to loss of GH lipolytic effects) and reduced muscle mass. Neonates and infants frequently present with fasting hypoglycemia (GH serves as a crucial counter-regulatory hormone to insulin) and prolonged conjugated hyperbilirubinemia. In males, microphallus and cryptorchidism may signal congenital hypopituitarism.

Diagnostic Workup

1. Bone Age Radiography: Radiograph of the left hand and wrist. In GH deficiency, bone age is significantly delayed (typically > 2 standard deviations below chronological age), confirming growth potential remains open.
2. Serological Screening: Measurement of Insulin-Like Growth Factor 1 (IGF-1) and Insulin-Like Growth Factor-Binding Protein 3 (IGFBP-3). Because GH is secreted in nocturnal pulses, random GH levels are clinically useless; IGF-1 and IGFBP-3 reflect integrated GH tissue action.
3. Provocative GH Stimulation Testing: Definitive diagnosis requires pharmacological stimulation using two distinct agents (e.g., clonidine, arginine, glucagon, or levodopa). A failure of serum GH to rise above 7 to 10 ng/mL confirms the diagnosis.
4. Cranial Magnetic Resonance Imaging (MRI): Mandatory evaluation of the hypothalamic-pituitary axis with thin-cut sagittal and coronal views to rule out structural tumors, predominantly craniopharyngioma (a benign cystic sellar/suprasellar tumor that compresses the optic chiasm and pituitary stalk).

Recombinant Human Growth Hormone (Somatropin) Therapy

• Administration: Daily subcutaneous injections of Somatropin (0.16 to 0.24 mg/kg/week divided into 6 or 7 daily doses).
• Bedtime Administration Rule: Somatropin must be administered subcutaneously at bedtime. This timing closely replicates the natural physiological surge of endogenous growth hormone that occurs 60 to 90 minutes after sleep onset during deep, slow-wave sleep (stages 3 and 4 NREM).
• Site Rotation: Rotate subcutaneous injection sites across the abdomen, outer thighs, and buttocks to prevent localized lipoatrophy.
• Duration: Continued until linear growth velocity drops below 2 cm/year and epiphyseal growth plates have fully fused on radiography (typically bone age of 14–15 years in females and 16–17 years in males).

Critical Nursing Surveillance for Adverse Effects